• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
  • Contact Us
From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H
Disease Status Explained by Neo-epitopes with Low Potential for Activating Regulatory T cells: an Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer

Disease Status Explained by Neo-epitopes with Low Potential for Activating Regulatory T cells: an Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer

by Annie De Groot | Oct 8, 2018

EpiVax_poster_Disease Status Explained by Neo-Epitopes with Low Potential for Activating Regulatory T Cells
Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer: Non-Self-Like Neo-epitopes as a Prognostic Biomarker

Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer: Non-Self-Like Neo-epitopes as a Prognostic Biomarker

by Annie De Groot | Oct 8, 2018

EpiVax_Ancer_CICON_Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer_26Sep18

Recent Posts

  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
  • Thinking Out Loud in March
  • Optimize Your Immunogenicity Strategy with Trusted Expert Advice 
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
  • Thinking Out Loud in February

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline